



Program

Wednesday, 12 October

9.00 – 12.00 *Registration*

12.00 - 13.00 *Lunch*

Room KALLIRROE

Time	Lecture	Speaker
<i>Chair Christoph Buchta</i>		
13.00 - 13.05	Opening Symposium	Christoph Buchta (EQALM Chair)
13.05 - 13.35	EQA for rare diseases	Ursula Unterberger (Austria)
13.35 - 14.00	Update on the In Vitro Diagnostic Medical Devices Regulation	Christa Cobbaert (Netherlands)

Time	Working Group / TFG	Working group Chair	Room
14.15 - 15.30	Haemostasis	Ann Helen Kristoffersen (Norway)	Conference Room Ground
14.15 - 15.30	Immunohaematology	Christoph Buchta (Austria)	Templar's
14.15 - 15.30	Virtual Microscopy	Istvan Juhos (Hungary)	Kallirroe
15.45 - 17.00	Haematology	Barbara Delasalle (United Kingdom)	Templar's
15.45 - 17.00	Performance Specifications	Dalius Vitkus (Lithuania)	Kallirroe
15.45 - 17.00	Virology	Christoph Buchta (Austria)	Conference Room Ground
17.15 - 18.30	Frequency	Wim Coucke (Belgium)	Conference Room Ground
17.15 - 18.30	TFG: ISO17043	Stephanie Albarede (France)	Templar's
17.15 - 18.30	EQA for POCT	Tony Badrick (Australia)	Kallirroe



Thursday, 13 October

Room KALLIRROE

Time	Lecture	Speaker
<i>Chair Stéphanie Albarède</i>		
8.30 - 9.00	Update on ISO17043	Olivier Pierson (BIPEA, France)
9.00 - 9.25	An example of providing EQA reports that become part of the participants quality management system	Tony Badrick (Australia)
9.25 - 9.50	Extended use of EQA-results	Mathias Karlsson (Sweden)
9.50 - 10.15	Experiences in EQA for phlebotomy and urine sampling?	Jonna Pelanti (Finland)
<hr/>		
10.15 - 10.45	<i>Break</i>	
<hr/>		
<i>Chair Gitte Henriksen</i>		
10.45 - 11.00	Development of an External Quality Assessment (EQA) Programme for Point of Care (POCT) Respiratory Viruses	Gareth Davies (United Kingdom)
11.00 - 11.15	Meta-analysis of within-subject and between-subject biological variation data for haemostasis variables	Martine J. Hollestelle (Netherlands)
11.15 - 11.30	Intra-type variability as a measure of the resilience to operator and environmental influences of POCT diagnostic devices	Christoph Buchta (Austria)
11.30 - 11.45	Patient based EQA	Rachel Marrington (United Kingdom)
11.45 - 12.00	Assessment and risk estimation of biotin interference in immunoassays	Alexander Haliassos (Greece)
<hr/>		
12.00 - 13.00	<i>Lunch</i>	



EQALM Symposium 2022
Hotel Royal Olympic, Athens, Greece
October 12th -14th

Thursday, 13 October

Room KALLIRROE

Time	Lecture	Speaker
<i>Chair Gro Gidske</i>		
13.00 - 13.30	Expanding the availability, coverage and uptake of EQA programmes in Africa	Beatrice Puije (ASLM)
13.30 - 13.50	EQALM SARS-CoV-2 antibody study	Lukas Weseslindtner (Austria)
13.50 - 14.05	Interest in low antibody control samples in viral serology - Methods of production/validation of samples	Marcel Miedougé (France)
14.05 - 14.20	WG Virtual microscopy: EQALM VM Sharing Platform and Guidelines	Istvan Juhos (Hungary)
14.20 - 14.35	WG Haemostasis: HIL program coagulation	Ann Helen Kristoffersen (Norway)
<i>14.35 - 15.30</i>	<i>Break + Poster viewing</i>	
15.30 - 16.30	General Assembly	

Adam Uldall Lecture:

Chair Christoph Buchta

16.30 - 17.30	EQA, is there a benefit for the patient?!	Piet Meijer (Netherlands)
---------------	---	---------------------------

Social Event:

Dinner at a Plaka traditional tavern



EQALM Symposium 2022
Hotel Royal Olympic, Athens, Greece
October 12th -14th

Friday, 14 October

Room KALLIROE

Time	Lecture	Speaker
<i>Chair Pierre Alain Morandi</i>		
8.30 - 9.00	Category 5 or 6 EQA programs	Tony Badrick (Australia)
9.00 - 9.30	Why EQA providers should use commutable control material and how to perform commutability studies	Sverre Sandberg (Norway)
9.30 - 10.00	What to do when reference measurement procedures show different results	Anja Kessler (Germany)
10.00 - 10.15	EQALM Central Database	Wim Coucke (Belgium)
10.15 - 10.45	<i>Break</i>	
<i>Chair Rachel Marrington</i>		
10.45 - 11.00	Harmonising reference intervals in Haematology	Barbara Delasalle (United Kingdom)
11.00 - 11.15	Correlation between EQA data as a key to determine optimum EQA frequency	Wim Coucke (Belgium)
11.15 - 11.45	Analytical performance specifications - what does a limit of total error mean and when can it be used	Mohamed Rida Soumali (Belgium)
11.45 - 12.15	EQA for POCT glucose – consequences for patient diagnostics	Anne Stavelin (Norway)
12.15 – 12.20	Closing of the symposium	Christoph Buchta (EQALM Chair)
